** Shares of LTR Pharma LTP.AX fall as much as 8.6% to A$0.96, their lowest level since Aug. 12
** Aussie biotech firm gets binding commitments for A$25 mln private placementat A$0.92/shr, a 12.4% discount to last close
** Says funds to speed development, commercialisation of its SPONTAN nasal spray treatment for erectile dysfunction
** Trading vol of 915,000+ shares tops 30-day avg of ~632,000
** Stock has now surged ~190% YTD
(Reporting by Nikita Maria Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))